Investor Presentaiton
19
Commercial execution and innovation
Diabetes care
Insulin icodec, a basal insulin intended for once-weekly
treatment, may reduce the disease burden for patients
Bringing the strongest value
proposition to market
Insulin icodec phase 3 programme expected to complete during 2022
TIR: Time-in-range
ONWARDS 1
970 people insulin-naïve, 78-week, vs insulin glargine U100
Reduction of disease burden with
once-weekly treatment
520 people on basal, 26-
ONWARDS 2
Tested for superior HbA₁ and TiR vs
glargine and standard-of-care and
week, vs insulin degludec
580 people insulin-naïve, 26-week,
ONWARDS 3
similar safety profile of TresibaⓇ
vs insulin degludec
ONWARDS 4
App-based offering and connected
smart pen to optimise titration and
support compliance and data
collection
ONWARDS 5
ONWARDS 6
Reduced
environmental footprint
580 people on both basal and bolus, 26-week,
vs insulin degludec
1,100 people, insulin-naïve using app-based dosing
recommendations, 52-week
580 people, type 1 diabetes using bolus insulin, 52-week,
vs insulin degludec
2022
Novo NordiskⓇ
CMD22
CAPITAL MARKETS DAYView entire presentation